ImaBiotech’s first worldwide patent has been granted for its quantification innovation in MSI

Lille, France – 29th March, 2016 – First worldwide patent has been granted covering ImaBiotech’s research and services platform in the field of Mass spectrometry Imaging (MSI).
ImaBiotech, a CRO company developing and offering new imaging technologies, applications, and software, announces today that the company has been granted a patent in USA, France, Australia and China for its lead innovation on quantitative MS Imaging (QMSI) and the development of the associated software, Multimaging.
Specifically, the QMSI patent covers the working method, the strategy, the method of validation, the application, and the use of quantitative Mass Spectrometry Imaging including MALDI Imaging.
“This is a positive recognition of our hard work,” said Jonathan Stauber, Chief Executive Officer of ImaBiotech. “The progress and recognition of our QMSI and MALDI Imaging services are now supporting ImaBiotech’s growth and development of our US operations and facility. This patent coverage is critical for our ongoing efforts.”

Located in Europe (France) and North America (Cambridge, MA), ImaBiotech (www.imabiotech.com) develops and offers services with new imaging technologies (Quantinetix™, Multimaging™) and applications. In order to accelerate drug development, ImaBiotech offers Mass Spectrometry Services to provide a cost effective solution to preclinical and clinical studies. This molecular technique is used for qualitative & quantitative efficacy and toxicity of drug candidates from the whole body to cell levels.

ImaBiotech
885 avenue Eugène Avinée
59120 Loos
Edma Fontaine,
ImaBiotech
Communication Manager
E: contact@imabiotech.com
T: +33 (0) 320 164 091

This release was published on openPR.